Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
IS02 - Industry Symposium Sponsored by AstraZeneca: Evolving the Role of Immunotherapy in Lung Cancer: ES-SCLC and Unresectable Stage III NSCLC
- 10:30 - 11:30
- 1/28/2021
- Location: Industry Symposia Auditorium (via Industry Hub)
- Not for CME Credit
- Type: Industry Symposium
- Track:
-
+
IS02.01 - Opening Remarks
10:30 - 10:35 | Presenter: Masahiro Tsuboi
- Abstract
No abstract available for this presentation
-
+
P03 - Early Stage/Localized Disease - Clinical Trials in Progress
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease
-
+
P03.02 - Neoadjuvant Osimertinib with/without Chemotherapy vs Chemotherapy for EGFR Mutated Resectable NSCLC: NeoADAURA
00:00 - 00:00 | Presenter: Masahiro Tsuboi
- Abstract
Loading... -
+
P03.03 - MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD+ Post-Surgery
00:00 - 00:00 | Presenter: Solange Peters
- Abstract
Loading... -
+
P03.05 - CANOPY-N: Neoadjuvant Canakinumab and Pembrolizumab in Patients With Surgically Resectable Non-Small Cell Lung Cancer
00:00 - 00:00 | Presenter: Jay M. Lee
- Abstract
Loading...
-
+
OA06 - Updates on EGFR Targeted Perioperative Therapy and Precision Adjuvant Chemotherapy
- 16:45 - 17:45
- 1/29/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Early Stage/Localized Disease
-
+
OA06.03 - Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC
16:45 - 16:55 | Presenter: Margarita Majem
- Abstract
Loading... -
+
OA06.04 - Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
16:55 - 17:05 | Presenter: Yi-long Wu
- Abstract
Loading...
-
+
PL04 - A Vision for Clinical Trials in 2020 and Beyond (Japanese, Mandarin, Spanish Translation Available)
- 07:00 - 09:00
- 1/31/2021
- Location: Scientific Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
-
+
PL04.08 - The Future of Clinical Trials - The Surgical Perspective
08:15 - 08:30 | Presenter: Masahiro Tsuboi
- Abstract
No abstract available for this presentation